| A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy (NCT03813784) | Jiangsu HengRui Medicine Co., Ltd. | 2019-03-07 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects. (NCT03848793) | Jiangsu HengRui Medicine Co., Ltd. | 2019-03-06 |
| Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia (NCT03825744) | Jiangsu HengRui Medicine Co., Ltd. | 2019-03-05 |
| The PK/PD Study of SHR2285 Tablets in Healthy Subjects (NCT03769831) | Jiangsu HengRui Medicine Co., Ltd. | 2019-02-25 |
| A Study of SHR-A1403 in Patients With Advanced Solid Tumor (NCT03856541) | Jiangsu HengRui Medicine Co., Ltd. | 2019-02-13 |
| SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors (NCT03774979) | Jiangsu HengRui Medicine Co., Ltd. | 2019-01-24 |
| Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors (NCT03827837) | Jiangsu HengRui Medicine Co., Ltd. | 2019-01-23 |
| Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) (NCT03711305) | Jiangsu HengRui Medicine Co., Ltd. | 2018-12-30 |
| Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer (NCT03691090) | Jiangsu HengRui Medicine Co., Ltd. | 2018-12-03 |
| A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC (NCT03666728) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-30 |
| A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma (NCT03711279) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-22 |
| SHR-1701 in Metastatic or Locally Advanced Solid Tumors (NCT03710265) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-20 |
| A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC (NCT03741712) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-20 |
| Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors (NCT03491631) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-20 |
| Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies (NCT03722186) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-13 |
| Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma (NCT03707509) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-13 |
| A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC (NCT03668496) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-09 |
| SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer (NCT03645876) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-08 |
| SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer (NCT03732508) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-01 |
| Safety, Tolerability and PK/PD of SHR1459 in Healthy Volunteers (NCT03668509) | Jiangsu HengRui Medicine Co., Ltd. | 2018-09-01 |
| The PK/PD Study of A Single Subcutaneous Injection of SHR-1209 in Healthy Subjects (NCT03634436) | Jiangsu HengRui Medicine Co., Ltd. | 2018-08-30 |
| The PK/PD Study of SHR0532 Tablets in Healthy Subjects (NCT03645278) | Jiangsu HengRui Medicine Co., Ltd. | 2018-08-24 |
| SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. (NCT03558191) | Jiangsu HengRui Medicine Co., Ltd. | 2018-08-14 |
| A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms (NCT03603951) | Jiangsu HengRui Medicine Co., Ltd. | 2018-08-14 |
| A Safety Study of Multiple Subcutaneous (s.c.) Injections of SHR-1314 in Adults With Moderate-to-severe Plaque Psoriasis (NCT03710681) | Jiangsu HengRui Medicine Co., Ltd. | 2018-08-02 |
| SHR9549 in ER Positive HER2 Negative Advanced Breast Cancer (NCT03596658) | Jiangsu HengRui Medicine Co., Ltd. | 2018-07-25 |
| Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer (NCT03588091) | Jiangsu HengRui Medicine Co., Ltd. | 2018-07-24 |
| A Study to Evaluate Different Intervals Between Dosing and Feeding on the Pharmacokinetics (NCT03603132) | Jiangsu HengRui Medicine Co., Ltd. | 2018-07-14 |
| Study of Remimazolam Tosilate in Patients Undergoing Colonoscopy (NCT03779061) | Jiangsu HengRui Medicine Co., Ltd. | 2018-06-28 |
| A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient (NCT03557099) | Jiangsu HengRui Medicine Co., Ltd. | 2018-06-20 |
| A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer (NCT03520478) | Jiangsu HengRui Medicine Co., Ltd. | 2018-05-30 |
| SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma (NCT03363555) | Jiangsu HengRui Medicine Co., Ltd. | 2018-05-29 |
| SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy (NCT03417895) | Jiangsu HengRui Medicine Co., Ltd. | 2018-04-20 |
| Safety, Tolerability and PK of SHR1314 in axSpA (NCT03704428) | Jiangsu HengRui Medicine Co., Ltd. | 2018-04-19 |
| A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer (NCT03509636) | Jiangsu HengRui Medicine Co., Ltd. | 2018-04-04 |
| A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer (NCT03472365) | Jiangsu HengRui Medicine Co., Ltd. | 2018-04-02 |
| A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer (NCT03481998) | Jiangsu HengRui Medicine Co., Ltd. | 2018-03-22 |
| A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE) (NCT03463876) | Jiangsu HengRui Medicine Co., Ltd. | 2018-03-08 |
| Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors (NCT03474289) | Jiangsu HengRui Medicine Co., Ltd. | 2018-03-01 |
| Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor (NCT03664297) | Jiangsu HengRui Medicine Co., Ltd. | 2018-02-06 |
| To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC (NCT05169801) | Jiangsu HengRui Medicine Co., Ltd. | 2018-01-25 |
| Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer (NCT05074589) | Jiangsu HengRui Medicine Co., Ltd. | 2018-01-25 |
| Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors (NCT03398720) | Jiangsu HengRui Medicine Co., Ltd. | 2017-12-31 |
| Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis (NCT03463187) | Jiangsu HengRui Medicine Co., Ltd. | 2017-12-15 |
| Drug-drug Interaction Between Simvastatin and SHR3824 (NCT03329118) | Jiangsu HengRui Medicine Co., Ltd. | 2017-11-24 |
| Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients (NCT03254966) | Jiangsu HengRui Medicine Co., Ltd. | 2017-11-24 |
| Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes (NCT04390295) | Jiangsu HengRui Medicine Co., Ltd. | 2017-11-02 |
| Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy (NCT03425474) | Jiangsu HengRui Medicine Co., Ltd. | 2017-09-01 |
| A Study To Test The Effect Of Apatinib On P450 Enzymes (NCT03245307) | Jiangsu HengRui Medicine Co., Ltd. | 2017-08-22 |
| Safety, Pharmacokinetics and Pharmacodynamics of Intranasal Dexmedetomidine in Healthy Subjects (NCT03293277) | Jiangsu HengRui Medicine Co., Ltd. | 2017-07-26 |
| The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors (NCT03182673) | Jiangsu HengRui Medicine Co., Ltd. | 2017-07-24 |
| Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia (NCT03185793) | Jiangsu HengRui Medicine Co., Ltd. | 2017-07-20 |
| Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient (NCT03222843) | Jiangsu HengRui Medicine Co., Ltd. | 2017-06-30 |
| PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma (NCT03155425) | Jiangsu HengRui Medicine Co., Ltd. | 2017-06-09 |
| Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes (NCT03159052) | Jiangsu HengRui Medicine Co., Ltd. | 2017-06-01 |
| A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC (NCT03134872) | Jiangsu HengRui Medicine Co., Ltd. | 2017-05-12 |
| Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer (NCT03099382) | Jiangsu HengRui Medicine Co., Ltd. | 2017-05-05 |
| Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) (NCT03080805) | Jiangsu HengRui Medicine Co., Ltd. | 2017-05-03 |
| A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC (NCT03085069) | Jiangsu HengRui Medicine Co., Ltd. | 2017-05-03 |
| A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects (NCT03121716) | Jiangsu HengRui Medicine Co., Ltd. | 2017-04-26 |
| A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC (NCT03092895) | Jiangsu HengRui Medicine Co., Ltd. | 2017-04-24 |
| A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) (NCT03083041) | Jiangsu HengRui Medicine Co., Ltd. | 2017-03-13 |
| A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients (NCT03075462) | Jiangsu HengRui Medicine Co., Ltd. | 2017-03-09 |
| The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout (NCT03131583) | Jiangsu HengRui Medicine Co., Ltd. | 2017-02-17 |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients (NCT03026881) | Jiangsu HengRui Medicine Co., Ltd. | 2017-01-01 |
| Food-Effect and Metabolism Study in Healthy Subjects (NCT03062982) | Jiangsu HengRui Medicine Co., Ltd. | 2016-12-21 |
| A Study to Evaluate SHR-1210 in Subjects With Advanced HCC (NCT02989922) | Jiangsu HengRui Medicine Co., Ltd. | 2016-11-15 |
| Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer (NCT02764268) | Jiangsu HengRui Medicine Co., Ltd. | 2016-11-02 |
| Phase I Study of SHR7390 in Patients With Advanced Solid Tumors (NCT02968485) | Jiangsu HengRui Medicine Co., Ltd. | 2016-11-01 |
| A Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy (NCT03003884) | Jiangsu HengRui Medicine Co., Ltd. | 2016-11-01 |
| A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation (NCT02834936) | Jiangsu HengRui Medicine Co., Ltd. | 2016-10-20 |
| Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy Subjects (NCT02892370) | Jiangsu HengRui Medicine Co., Ltd. | 2016-08-01 |
| A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer (NCT02973737) | Jiangsu HengRui Medicine Co., Ltd. | 2016-07-20 |
| Effect of Itraconazole on the Pharmacokinetics of Apatinib (NCT02836171) | Jiangsu HengRui Medicine Co., Ltd. | 2016-07-01 |
| Multiple Dose Study of SHR4640 in Healthy Subjects (NCT02890966) | Jiangsu HengRui Medicine Co., Ltd. | 2016-07-01 |
| The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers (NCT02826044) | Jiangsu HengRui Medicine Co., Ltd. | 2016-07-01 |
| A PhaseⅡ/ Ⅲ Seamless Study to Evaluate Efficacy and Safety of Paracetamol Injection as Adjuvant to Morphine-based Postoperative Analgesia (NCT02811991) | Jiangsu HengRui Medicine Co., Ltd. | 2016-06-01 |
| SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer (NCT02766140) | Jiangsu HengRui Medicine Co., Ltd. | 2016-06-01 |
| A Study of Irinotecan Hydrochloride Liposome in Combination With 5-FU/LV in Advanced Solid Tumors (NCT05086848) | Jiangsu HengRui Medicine Co., Ltd. | 2016-05-05 |
| Effect of Rifampicin on the Pharmacokinetics of Apatinib (NCT02836821) | Jiangsu HengRui Medicine Co., Ltd. | 2016-05-01 |
| Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients (NCT02665910) | Jiangsu HengRui Medicine Co., Ltd. | 2016-05-01 |
| The Efficacy and Safety of Pregabalin Release Tablets for the Treatment of Fibromyalgia (NCT02868814) | Jiangsu HengRui Medicine Co., Ltd. | 2016-05-01 |
| A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects (NCT02742935) | Jiangsu HengRui Medicine Co., Ltd. | 2016-04-27 |
| A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma (NCT02738489) | Jiangsu HengRui Medicine Co., Ltd. | 2016-04-13 |
| A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients (NCT02691975) | Jiangsu HengRui Medicine Co., Ltd. | 2016-04-12 |
| A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects (NCT02721589) | Jiangsu HengRui Medicine Co., Ltd. | 2016-04-06 |
| The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients (NCT02822534) | Jiangsu HengRui Medicine Co., Ltd. | 2016-04-01 |
| A Study of SHR6390 in Advanced Solid Tumor Patients (NCT02684266) | Jiangsu HengRui Medicine Co., Ltd. | 2016-03-03 |
| The DDI Study of SP2086 and Simvastatin (NCT02817243) | Jiangsu HengRui Medicine Co., Ltd. | 2016-03-01 |
| The DDI Study of SP2086 and Valsartan (NCT02817217) | Jiangsu HengRui Medicine Co., Ltd. | 2016-03-01 |
| the Food Effect Pharmacokinetic, Material Balance and Metabolite Identification of SP2086 in Healthy Volunteers (NCT02821871) | Jiangsu HengRui Medicine Co., Ltd. | 2016-03-01 |
| A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients (NCT02671513) | Jiangsu HengRui Medicine Co., Ltd. | 2016-01-01 |
| The Drug-drug Interaction of SP2086 and Metformin (NCT02813863) | Jiangsu HengRui Medicine Co., Ltd. | 2015-12-01 |
| Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides (NCT02625870) | Jiangsu HengRui Medicine Co., Ltd. | 2015-12-01 |
| Single Dose Study of SHR4640 in Healthy Subjects (NCT02815839) | Jiangsu HengRui Medicine Co., Ltd. | 2015-11-01 |
| The Metabolite Identification and Material Balance Study of SP2086 (NCT02815748) | Jiangsu HengRui Medicine Co., Ltd. | 2015-08-01 |
| Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients (NCT02614846) | Jiangsu HengRui Medicine Co., Ltd. | 2015-08-01 |
| Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment (NCT03160014) | Jiangsu HengRui Medicine Co., Ltd. | 2015-06-01 |
| Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient (NCT03159832) | Jiangsu HengRui Medicine Co., Ltd. | 2015-06-01 |
| A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer (NCT02426034) | Jiangsu HengRui Medicine Co., Ltd. | 2015-05-15 |